302 related articles for article (PubMed ID: 22085167)
21. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine.
Nakagomi T; Cuevas LE; Gurgel RG; Elrokhsi SH; Belkhir YA; Abugalia M; Dove W; Montenegro FM; Correia JB; Nakagomi O; Cunliffe NA; Hart CA
Arch Virol; 2008; 153(3):591-3. PubMed ID: 18175037
[TBL] [Abstract][Full Text] [Related]
22. Rotavirus vaccines for the developing world.
O'Ryan ML; Hermosilla G; Osorio G
Curr Opin Infect Dis; 2009 Oct; 22(5):483-9. PubMed ID: 19623063
[TBL] [Abstract][Full Text] [Related]
23. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Chandran A; Santosham M
Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
[TBL] [Abstract][Full Text] [Related]
24. Characterization of G2P[4] rotavirus strains associated with increased detection in Australian states using the RotaTeq® vaccine during the 2010-2011 surveillance period.
Donato CM; Zhang ZA; Donker NC; Kirkwood CD
Infect Genet Evol; 2014 Dec; 28():398-412. PubMed ID: 24861815
[TBL] [Abstract][Full Text] [Related]
25. The pentavalent rotavirus vaccine, RotaTeq.
Matson DO
Semin Pediatr Infect Dis; 2006 Oct; 17(4):195-9. PubMed ID: 17055370
[TBL] [Abstract][Full Text] [Related]
26. Rotarix: a rotavirus vaccine for the world.
Ward RL; Bernstein DI
Clin Infect Dis; 2009 Jan; 48(2):222-8. PubMed ID: 19072246
[TBL] [Abstract][Full Text] [Related]
27. Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review.
Nakagomi O; Iturriza-Gomara M; Nakagomi T; Cunliffe NA
Expert Opin Biol Ther; 2013 Nov; 13(11):1613-21. PubMed ID: 24088009
[TBL] [Abstract][Full Text] [Related]
28. Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions.
Cherian T; Wang S; Mantel C
Vaccine; 2012 Apr; 30 Suppl 1():A3-6. PubMed ID: 22520133
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study.
Gastañaduy PA; Steenhoff AP; Mokomane M; Esona MD; Bowen MD; Jibril H; Pernica JM; Mazhani L; Smieja M; Tate JE; Parashar UD; Goldfarb DM
Clin Infect Dis; 2016 May; 62 Suppl 2():S161-7. PubMed ID: 27059351
[TBL] [Abstract][Full Text] [Related]
30. Rotavirus vaccine: early introduction in Latin America-risks and benefits.
Pérez-Vargas J; Isa P; López S; Arias CF
Arch Med Res; 2006 Jan; 37(1):1-10. PubMed ID: 16314179
[TBL] [Abstract][Full Text] [Related]
31. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia.
Snelling TL; Andrews RM; Kirkwood CD; Culvenor S; Carapetis JR
Clin Infect Dis; 2011 Jan; 52(2):191-9. PubMed ID: 21288843
[TBL] [Abstract][Full Text] [Related]
32. A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia.
Beres LK; Tate JE; Njobvu L; Chibwe B; Rudd C; Guffey MB; Stringer JS; Parashar UD; Chilengi R
Clin Infect Dis; 2016 May; 62 Suppl 2():S175-82. PubMed ID: 27059353
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Pentavalent Rotavirus Vaccine Against a Diverse Range of Circulating Strains in Nicaragua.
Patel M; Pedreira C; De Oliveira LH; Tate J; Leshem E; Mercado J; Umaña J; Balmaceda A; Reyes M; Kerin T; McDonald S; Gentsch J; Bowen MD; Parashar U
Clin Infect Dis; 2016 May; 62 Suppl 2():S127-32. PubMed ID: 27059346
[TBL] [Abstract][Full Text] [Related]
34. The rotavirus experience in Mexico: discovery to control.
Patel MM; Parashar UD; Santosham M; Richardson V
Clin Infect Dis; 2013 Feb; 56(4):548-51. PubMed ID: 23271788
[TBL] [Abstract][Full Text] [Related]
35. A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix.
Nakagomi T; Nakagomi O
Expert Opin Biol Ther; 2009 Aug; 9(8):1073-86. PubMed ID: 19591630
[TBL] [Abstract][Full Text] [Related]
36. Influence of potential protective mechanisms on the development of live rotavirus vaccines.
Ward RL; Clark HF; Offit PA
J Infect Dis; 2010 Sep; 202 Suppl():S72-9. PubMed ID: 20684721
[TBL] [Abstract][Full Text] [Related]
37. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
[TBL] [Abstract][Full Text] [Related]
38. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants.
Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of an ideal rotavirus vaccine.
Reisinger KS; Block SL
Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
[TBL] [Abstract][Full Text] [Related]
40. Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?
Matthijnssens J; Nakagomi O; Kirkwood CD; Ciarlet M; Desselberger U; Van Ranst M
Expert Rev Vaccines; 2012 Nov; 11(11):1347-54. PubMed ID: 23249234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
